Ulwazi Travel Wikepedia

Uphononongo olutsha lufumana ukusweleka koMhlaza wamabele kwihlabathi lonke kwanda

Ibhalwe ngu umhleli

Amatyala omhlaza ayanda, ngokutsho kophononongo olutsha oluthelekisa inani lokuxilongwa komhlaza kwihlabathi liphela ngo-2010 no-2019. Phakathi kwedatha, abaphandi bangqina ukuba amazinga omhlaza wehlabathi anyuke nge-26% kwaye umhlaza wamabele wawungoyena nobangela uphambili womhlaza. -iminyaka yobomi enxulumene nokukhubazeka (DALYs), ukufa, kunye neminyaka yobomi elahlekileyo (YLLs) phakathi kwabasetyhini kwihlabathi liphela ngo-2019.

Print Friendly, PDF & Email

NgokukaPhando kunye neeMakethi, imakethi yehlabathi yamachiza omhlaza webele kulindeleke ukuba ikhule iye kuthi ga kwi-19.49 yeebhiliyoni zeedola ngo-2025 kwi-CAGR ye-7.1%. Phakathi kwabaphuhlisi bebhayoloji abasebenza ngo-2022 kunyango olutsha lomhlaza wamabele yi-Oncolytics Biotech Inc., iRoche Holding AG, iPfizer Inc., i-Incyte Corporation, kunye ne-AstraZeneca PLC.

Phakathi komhlaza ekujoliswe kuwo yi-Oncolytics Biotech Inc. kunye ne-flagship immunotherapeutic agent pelareorep, umhlaza wamabele yeyona nto iphambili ekugxilwe kuyo yinkampani, ngokweleta yayo yamva nje eya kubanini-zabelo abaye baphonononga impumelelo yabo ngo-2021 kwaye yachaza inkqubo yabo ezayo ka-2022.

Ngaphakathi kweNkqubo yoMhlaza wamabele ukuza kuthi ga ngoku, i-Oncolytics ibone ukuphinda-phindwe kabini kokusinda ngokubanzi kwi-metastatic HR +/HER2- izigulane zomhlaza webele eziphathwe nge-pelareorep kwi-IND-213-njengoko kubonwe kwiziphumo zokufunda ezinikezelwe kwi-2017.

Emva kokuhlalutya idatha ngakumbi, i-Oncolytics yakhetha ukugxila kwiinjongo ezintathu ezinokufezekiswa ezibekwe ngabalawuli kunye namaqabane e-pharma yenkampani, emele amanyathelo abalulekileyo ekufundweni kokubhalisa. Oku kubandakanya: 1. Ukuqinisekisa ukuba i-pelareorep isebenza nge-immunotherapeutic mechanism of action; 2. Ukugqiba ukuba i-pelareorep idibanisa kunye ne-immune checkpoint inhibitors; kunye 3. Ukuchonga i-biomarker ukukhetha izigulane ezinokuthi zibe neziphumo ezingcono zeklinikhi.

Ukusukela ngo-Epreli ka-2021, i-Oncolytics ibonise idatha yeqela kuphononongo lwayo lwe-AWARE-1, oluqhutywa ne-Roche Holding AG (OTC:RHHBY), ebonisa ukuba inkampani ifezekise iinjongo ezimbini zokuqala ezichazwe ngasentla.

Kamva ngoDisemba kwi-2021 San Antonio Breast Cancer Symposium (SABCS), i-Oncolytics ibonise uhlaziyo oluqinisekileyo lokhuseleko oluvela kwi-IRENE iSigaba se-2 esiThathu esiNegative soLwango loMhlaza wamabele oluvavanya ukhuseleko kunye nokusebenza kakuhle kwe-pelareorep ngokudityaniswa ne-anti-PD-1 yokuhlola inhibitor. i-retifanlimab evela kwi-Incyte Corporation yonyango lwesibini okanye lwesithathu lwezigulane ezinomhlaza webele we-metastatic triple-negative (TNBC).

Idatha yoKhuseleko evela kulingo ibonise ukuba udibaniso lunyamezelwe kakuhle, kungekho nkxalabo yokhuseleko ephawulwe kuyo nayiphi na izigulane ezibhaliswe kulingo ngexesha lokunika ingxelo.

Uphononongo lwe-IRENE luhlala luqhubeka kwaye luya kuqhubeka nokubhalisa izigulane kwi-Rutgers Cancer Institute yaseNew Jersey kunye ne-Ohio State University Comprehensive Cancer Centre.

I-Incyte Corporation isandula kunika olunye uhlaziyo olubandakanya i-retifanlimab zidityaniswe nomgqatswa okhokelayo we-BriaCell Therapeutics wezonyango i-Bria-IMTTM kwi-SABCS. Isishwankathelo ekuhlaziyweni, ukusinda ngokubanzi kwakuphezulu kakhulu kwizigulane kwisifundo esidibeneyo, siphakamisa i-additive okanye i-synergistic effect kunye nokuxhasa ukuqhubeka kwesifundo. Ngokwewebhusayithi yeBriaCell, ukhuseleko olongezelelweyo kunye nedatha esebenzayo kulindeleke ngo-2022.

I-Pfizer, Inc. isanda kungena kwintsebenziswano yovavanyo lweklinikhi kunye nesivumelwano sokubonelela kunye neCelcuity, apho i-pharma giant iya kubonelela nge-Palbociclib (Ibrance) ukuze isetyenziswe kwisigaba se-3 sophando lwekliniki oluqhutywa yiCelcuity ngaphandle kweendleko kwinkampani.

Ulingo lwezonyango lwesigaba sesi-3 kulindeleke ukuba luqalise kwisiqingatha sokuqala sika-2022 ukuhlola ukusetyenziswa kwe-pan-PI3K/mTOR inhibitor gedatolisib (PF-05212384) ngokudibanisa nepalbociclib kunye ne-fulvestrant kwizigulane ezine-estrogen receptor (ER)–positive, HER2 -negative advanced umhlaza webele. I-Celcuity iya kukhulula iinkcukacha ezongezelelweyo malunga nolingo lwekliniki emva kwentetho kunye nengxelo elandelayo evela kwi-FDA.

Ngasekupheleni kuka-2021, i-AstraZeneca PLC kunye namaqabane u-Daiichi Sankyo ubhengeze ukuba i-Arhente ye-European Medicines Agency (EMA) iyiqinisekisile i-Type II Variation yeSicelo se-trastuzumab deruxtecan (T-DXd; Enhertu) kunyango oluphambili, olunyangwa ngaphambili nge-HER2-positive breast. izigulane ezinomhlaza.

Ngeli xesha, isigulana sokuqala esine-HR+, i-HER2- umhlaza webele we-metastatic ongasebenziyo wajongwa nge-datopotamab deruxtecan (DS-1062a; dato-DXd) njengenxalenye yesigaba sesi-3 solingo lwe-TROPION-Breast01 (NCT05104866). I-TROP2-directed DXd ADC ephuhliswayo ngoku nguDaiichi Sankyo kunye ne-AstraZeneca okwangoku iphantsi kophando kulingo lwehlabathi jikelele, olungakhethiyo, oluvuleleke kwileyibhile ngedosi ye-6 mg/kg vs ukhetho lomphandi lwekhemotherapy.

Enye indlela yokuphucula amathuba kumlo ochasene nomhlaza, lugqatso lokuphucula ukufunyanwa kwangoko. Ngokutsho kweCarol Milgard Breast Centre ukufumanisa kwangoko kubalulekile.

I-Roche Holding AG isandula ukukhaba kwi-290 yezigidi zeedola kumjikelo wenkxaso-mali ogqithise i-1 yeebhiliyoni zeedola kubaphuhlisi be-biopsy engamanzi iFreenome. 

Print Friendly, PDF & Email

Iindaba ezidibeneyo

Malunga nombhali

umhleli

Umhleli oyintloko we-eTurboNew nguLinda Hohnholz. Uzinze kwi-eTN HQ e-Honolulu, eHawaii.

Shiya Comment